Company: TYRA
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001193125-25-152016
Chunk: 0

Company: Tyra Biosciences, Inc.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300in low-grade, intermediate risk non-muscleinvasive bladder cancer (IR NMIBC).

SURF302 is an open-label Phase 2 clinical study evaluating the efficacy and safety of TYRA-300in participants with FGFR3-altered low-grade, IR NMIBC. The study will enroll up to 90 participants at multiple sites primarily in the United States. Participants will be randomized initially to treatment with TYRA-300at 50 mg once daily (QD) (Cohort 1) or treatment withTYRA-300at 60 mg QD (Cohort 2). Following a review of efficacy and safety, an additional dosing cohort may be evaluated. The primary endpoint is complete response (CR) rate at three months. Secondary endpoints include time to recurrence, the median duration of response, recurrence free survival, progression free survival, safety and tolerability. The Company expects to report initial three-month CR data in the first half of 2026.